SAN - Banco Santander, S.A.
| Previous Close | 4.5800 |
| Open | 4.5300 |
| Bid | 4.47 x 1400 |
| Ask | 4.69 x 1000 |
| Day's Range | 4.5200 - 4.5900 |
| 52 Week Range | 4.3000 - 7.5700 |
| Volume | 6,156,494 |
| Avg. Volume | 8,580,338 |
| Market Cap | 73.912B |
| Beta (3Y Monthly) | 1.05 |
| PE Ratio (TTM) | 9.42 |
| EPS (TTM) | 0.48 |
| Earnings Date | Jan 25, 2017 - Feb 1, 2017 |
| Forward Dividend & Yield | 0.16 (3.58%) |
| Ex-Dividend Date | 2018-10-16 |
| 1y Target Est | 6.04 |
- Reuters•5 days ago
CEE MARKETS-Stocks rebound, crown eases despite rate hike suggestion
Warsaw led a rise of Central Europe's main stock indices on Wednesday as U.S. President Donald Trump generated optimism about a trade deal with China, helping global equities markets. Warsaw's bluechip ...
- Reuters•5 days ago
Santander Brasil CFO expects asset growth of up to 8 pct in 2019
Banco Santander Brasil may expand its assets by up to 8 percent next year, above the country's GDP growth rate, Chief Financial Officer Angel Santodomingo told investors on Tuesday. The announcement comes ...
- Reuters•8 days ago
Julius Baer in talks with Santander over Venezuela business: sources
Swiss private bank Julius Baer is in talks about transferring its Venezuelan book of business to Spain's Banco Santander as Baer reorganises operations in Latin America, sources close to the situation have told Reuters. Baer said in October it was closing its branches in Peru and Panama as part of its effort to focus on larger markets in the region such as Mexico, Brazil and Argentina. A source familiar with the situation, who asked not to be identified, said on Saturday that talks with Santander over Baer's Venezuelan book of business were under way but had not yet been concluded.
Reuters•8 days agoJulius Baer in talks with Santander over Venezuela business: sources
Swiss private bank Julius Baer (BAER.S) is in talks about transferring its Venezuelan book of business to Spain's Banco Santander (SAN.MC) as Baer reorganizes operations in Latin America, sources close to the situation have told Reuters. Baer said in October it was closing its branches in Peru and Panama as part of its effort to focus on larger markets in the region such as Mexico, Brazil and Argentina. A source familiar with the situation, who asked not to be identified, said on Saturday that talks with Santander over Baer's Venezuelan book of business were under way but had not yet been concluded.
- Reuters•11 days ago
Spanish online bank WiZink looks to float in 2019 -sources
FRANKFURT/LONDON/MADRID, Dec 5 (Reuters) - Investment firm Varde Partners is planning to float its Spanish online bank WiZink next year, with investment banks UBS and Goldman Sachs likely to be selected as IPO coordinators, people close to the matter said. WiZink is expected to have a market capitalisation of around 2.5-3 billion euros ($2.8-$3.4 billion) and the initial public offering (IPO) would come in the third quarter of 2019, one of the sources added. Goldman Sachs and WiZink declined to comment, while UBS did not immediately respond to a request for comment.
- PR Newswire•13 days ago
Santander Bank Names David Harnisch Head of Commercial Banking
BOSTON, Dec. 3, 2018 /PRNewswire/ -- Santander Bank today announced that it has named David Harnisch Head of Commercial Banking. Harnisch joined Santander in 2017 as the Head of Underwriting, Portfolio Management and Commercial Strategy, and will now be responsible for leading and growing its commercial banking division.
- Moody's•13 days ago
GUINCHO FINANCE -- Moody's assigns definitive ratings to Guincho Finance Portuguese ABS notes backed by NPLs issued by Hefesto, STC, S.A.
Rating Action: Moody's assigns definitive ratings to Guincho Finance Portuguese ABS notes backed by NPLs issued by Hefesto, STC, S.A. Moody's has not assigned any ratings to E25,000,000 Class J Asset-Backed Variable Return Notes due November 2038 and E3,100,000 Class R Notes due November 2038. The NPLs consist of defaulted secured loans, equal to E234.8 million, which are backed by residential, commercial/industrial properties and land located in Portugal.
Bloomberg•17 days agoSantander Sees Brazil Poised for $30 Billion Equity Sale Bonanza
“2019 is going to be a quite active year,” said Santander Brasil’s head of Equities Andre Rosenblit. This scenario has changed,” Rosenblit said in an interview at the bank’s Sao Paulo office. The outlook’s shift for equity offerings in Latin America’s largest economy has taken place amid investors’ expectations that President-elect Jair Bolsonaro’s administration will embrace a market-friendly agenda, aiming to privatize inefficient state-owned companies and pushing through fiscal measures to fix the country’s rising public debt, especially an overhaul in Brazil’s social security system.
- Moody's•20 days ago
FONDO DE TITULIZACION PYMES SANTANDER 14 -- Moody's assigns definitive ratings to SME ABS notes issued by FONDO DE TITULIZACION PYMES SANTANDER 14
The ratings of the Notes are primarily based on the analysis of the credit quality of the underlying portfolio, the structural integrity of the transaction, the roles of external counterparties and the protection provided by credit enhancement. The Notes' ratings are sensitive to the performance of the underlying portfolio, which in turn depends on economic and credit conditions that may change.
- Simply Wall St.•21 days ago
Is Banco Santander SA (BME:SAN) A Smart Pick For Income Investors?
A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, Banco Santander SA (BME:SAN) has been Read More...
- Moody's•23 days ago
FONDO DE TITULIZACION PYMES SANTANDER 13 -- Moody's upgrades FONDO DE TITULIZACION PYMES SANTANDER 13 Class A and B notes
Pymes Santander 13 is a cash securitisation of standard loans and credit lines granted by Banco Santander S.A. (Spain) ("Santander", Long Term Deposit Rating: A2 Not on Watch /Short Term Deposit Rating: P-1 Not on Watch) to small and medium-sized enterprises (SMEs) and self-employed individuals located in Spain. The upgrade is prompted by the increase in the credit enhancement (CE) available for the affected tranche due to portfolio amortization. Class A credit enhancement level has increased to 31% from 21.5% observed at last rating action in May 2018, a 49% increase in relative terms since the closing date of the transaction in January 2018.
- Reuters•26 days ago
U.S. watchdog fines Spain's Santander $11.8 mln over misleading loans, insurance
Santander Consumer USA Holdings Inc, a leading subprime auto lender, will pay $11.8 million to settle claims that it misled customers about the cost and terms of auto loans and insurance, a U.S. consumer watchdog said on Tuesday. Santander Consumer, an affiliate of the Spanish banking group Banco Santander SA, promised drivers lower monthly fees by allowing them to make interest-only payments without explaining this would increase the total cost of the loan, the Consumer Financial Protection Bureau (CFPB) said. Santander Consumer is one of the nation's largest subprime auto lenders and manages about $52 billion in loans to 2.7 million customers, the lender has said.
- Zacks•26 days ago
BBVA or SAN: Which Is the Better Value Stock Right Now?
BBVA vs. SAN: Which Stock Is the Better Value Option?
- Moody's•26 days ago
FONDO DE TITULIZACION PYMES SANTANDER 14 -- Moody's assigns provisional ratings to SME ABS notes to be issued by FONDO DE TITULIZACION PYMES SANTANDER 14
Moody's issues provisional ratings in advance of the final sale of financial instruments, but these ratings only represent Moody's preliminary credit opinions. The transaction is a cash securitisation of standard loans and credit lines granted by Banco Santander S.A. (Spain) ("Santander", Long Term Deposit Rating: A2 Not on Watch /Short Term Deposit Rating: P-1 Not on Watch) mainly to small and medium-sized enterprises (SMEs) and self-employed individuals located in Spain. The ratings of the Notes are primarily based on the analysis of the credit quality of the underlying portfolio, the structural integrity of the transaction, the roles of external counterparties and the protection provided by credit enhancement.
- GlobeNewswire•last month
Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
November 16, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.
- Insider Monkey•last month
Hedge Funds Are Buying Banco Santander, S.A. (SAN)
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
- Moody's•last month
GUINCHO FINANCE -- Moody's assigns provisional ratings to Guincho Finance Portuguese ABS Notes backed by NPLs to be issued by Hefesto, STC, S.A.
Rating Action: Moody's assigns provisional ratings to Guincho Finance Portuguese ABS Notes backed by NPLs to be issued by Hefesto, STC, S.A. Moody's has not assigned any ratings to E[25,000,000] Class J Asset-Backed Variable Return Notes due [November 2038] and E[3,100,000] Class R Notes due [November 2038].
- American City Business Journals•last month
Bank Notes: Wells Fargo shuffles C-suite, uncovers more mortgage issues
The bank said that its chief administrative officer and chief auditor have begun leaves of absence from the bank and named new leaders for key parts of the company.
Motley Fool•last monthWhy Banco Santander Brasil Shares Soared 29% in October
Brazilian politics provided an external boost to Santander's share price -- at least temporarily.
- GlobeNewswire•last month
Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.
- GlobeNewswire•last month
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse.
